See the results of personal testimonies given by advocates and key stakeholders who appeared before the Ohio House Finance Committee in support of the ALS Amendment which would drastically increase funding for ALS care in Ohio.
When the FDA recently accepted Biogen’s new drug application for tofersen, it signaled hope for thousands of people with SOD1 mutations that cause ALS. The FDA has granted priority review to this new drug application and is expected to decide on whether or not to approve tofersen by January 25, 2023.